SCHEMBL2227800

SCHEMBL2227800

Cc1ccnc(Nc2cccc(-c3cnc(C=O)s3)n2)c1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 12/20 0.58
SYK P43405 4/20 0.51
KDR P35968 1/20 0.48
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
KCNN1 Q92952 1/20 0.41
KCNN2 Q9H2S1 1/20 0.41
KCNN3 Q9UGI6 1/20 0.41
SLC2A1 P11166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14673450 0.85 KARS1 (0.51) KARS1SYKKDRMEN1NPC1
SCHEMBL14673451 0.85 KARS1 (0.51) KARS1SYKKDRMEN1NPC1
SCHEMBL13136251 0.84 KARS1 (0.60) KARS1SYKKDRMEN1NPC1
SCHEMBL2866501 0.84 KARS1 (0.57) KARS1SYKKDRMEN1NPC1
SCHEMBL2865910 0.82 KARS1 (0.58) KARS1SYKKDRMEN1NPC1
SCHEMBL2865766 0.81 KDR (0.59) KARS1SYKKDRMEN1NPC1
SCHEMBL13136547 0.80 KARS1 (0.61) KARS1SYKKDRMEN1NPC1
SCHEMBL2866521 0.80 KARS1 (0.56) KARS1SYKKDR
SCHEMBL13136090 0.80 KARS1 (0.56) KARS1SYKKDR
SCHEMBL13136147 0.80 KARS1 (0.55) KARS1SYKKDRMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US claimed
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP disclosed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO disclosed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK KARS1 1099/4885SYK 1/4885KDR 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.